Abstract 4447
Background
Seminomas do not express specific tumour markers, but in ∼30% of the patients (pts) serum HCG levels are elevated. This study investigates the prognostic impact of HCG levels and other characteristics in metastatic HCG-positive seminoma patients.
Methods
Patients with seminomatous histology, metastatic disease, serum HCG levels above normal without AFP elevations at diagnosis were eligible. Uni- and multivariable analyses were conducted to identify risk factors associated with survival outcomes. Cut-off values were determined by ROC curve analysis. Primary and secondary endpoints were overall survival (OS) and recurrence free survival (RFS), respectively.
Results
Our study identified 407 eligible patients diagnosed between 1984 and 2018 (334 pts good and 48 pts intermediate prognosis according to IGCCCG). The 5-year OS and 3-year RFS rates were 91% and 83%, respectively. HCG levels ranged from 1 IU/l to 283.782 IU/l (median: 33; IQR 142.5) pre- and 0 IU/l to 36.700 IU/l (median: 37; IQR 156.2) post-orchiectomy. Serum HCG levels pre-orchiectomy correlated with the UICC stage: mean HCG 826.9 IU/l in stage IIA-C vs. mean 4764.4 IU/l in stage IIIA-C (p < 0.001) and metastatic burden assessed by the largest axial diameter of metastasis: mean HCG 57.4 IU/l if < 7cm vs. mean 4.685 IU/l if ≥ 7cm (p = 0.012), respectively. Univariable analysis revealed LDH ≥1.5 UNL pre-orchiectomy (5-year OS: 87% vs. 97%, n = 91) (p = 0.019), age ≥40 years (5-year OS: 87% vs. 94%, n = 152) (p = 0.007), and HCG ≥2.000 IU/l pre-orchiectomy (5-year OS: 76% vs. 94%, n = 17) (p = 0.019) as poor prognostic factors concerning OS. Multivariable analysis confirmed LDH ≥1.5 UNL pre-orchiectomy (HR 3.88, 95%CI 1.97-16.25; p = 0.01), age ≥40 years (HR 5.97, 95%CI 1.82-17.15; p = 0.02), and HCG levels ≥2.000 IU/l pre-orchiectomy (HR 3.59, 95%CI 1.01-12.77; p = 0.048) as independent negative prognosticators for OS. No significant correlations were found between patient characteristics and the recurrence free survival.
Conclusions
HCG values correlate with the tumour stage and levels ≥2.000 IU/l are associated with an impaired outcome concerning OS. Our results should be considered for the risk stratification of HCG positive seminoma patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
T. Hermanns: Advisory / Consultancy: Bayer und MSD. U. De Giorgi: Research grant / Funding (self): AstraZeneca, Roche, Sanofi; Travel / Accommodation / Expenses: BMS, Ipsen, Janssen, Pfizer; Advisory / Consultancy: Astellas, Bayer, BMS, Ipsen, Janssen, Merck, Pfizer, Sanofi. R. Cathomas: Advisory / Consultancy: AstraZeneca, Astellas, Bayer, Janssen, Sanofi, BMS, MSD, Roche, Pfizer; Speaker Bureau / Expert testimony: Debiopharm, Astellas. C. Oing: Honoraria (self), Travel / Accommodation / Expenses: IPSEN, Medac; Research grant / Funding (institution): Roche. All other authors have declared no conflicts of interest.
Resources from the same session
4145 - Diagnosis, Management, and Burden of Renal Cell Carcinomas: Results from a Global Patient Survey in 43 countries
Presenter: Rachel Giles
Session: Poster Discussion – Genitourinary tumours, non-prostate
Resources:
Abstract
Poster Discussion – Genitourinary tumours, non-prostate - Invited Discussant 904PD, 905PD and 906PD
Presenter: Joaquim Bellmunt
Session: Poster Discussion – Genitourinary tumours, non-prostate
Resources:
Slides
Webcast
Poster Discussion – Genitourinary tumours, non-prostate - Invited Discussant 907PD, 908PD, 909PD and 910PD
Presenter: Guillermo A. De Velasco Oria de Rueda
Session: Poster Discussion – Genitourinary tumours, non-prostate
Resources:
Slides
Poster Discussion – Genitourinary tumours, non-prostate - Invited Discussant 911PD and 912PD
Presenter: Viktor Gruenwald
Session: Poster Discussion – Genitourinary tumours, non-prostate
Resources:
Slides
Webcast
Poster Discussion – Genitourinary tumours, non-prostate - Invited Discussant 913PD, 914PD and 915PD
Presenter: Christian Kollmannsberger
Session: Poster Discussion – Genitourinary tumours, non-prostate
Resources:
Slides
Webcast